10x Genomics filed patent litigation against Illumina in Delaware federal court, alleging infringement tied to single‑cell and spatial transcriptomics technologies as the two firms intensify competition in the multiomics market. The lawsuits represent another aggressive IP move from 10x, which has litigated multiple competitors over platform technologies. The disputes come amid broad vendor consolidation and product launches across sequencing and multiomics vendors; ramifications could include injunctions, licensing deals, or royalties that reshape commercial dynamics. Customers and service labs will watch potential supply, pricing and interoperability impacts if litigation disrupts technology deployments or forces design‑arounds.